Compare Enveric Biosciences Inc (ENVB) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Under Armour Inc Class A — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 304.4× Enveric Biosciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Under Armour Inc Class A for 99 Days on average.
| ENVB | UAA | |
|---|---|---|
Market Cap | $6.80M | $2.07B |
Volume | 64,867 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $8.14 |
52-Week Low | $1.27 | $4.17 |
Typical Hold Time | 14 Days | 99 Days |
Enterprise Value | -$1.49M | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Under Armour (UAA) trades at $4.82, down 1.23% on the day, with a mixed technical picture showing a bullish overall signal but a neutral RSI. The company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. Analyst consensus is a $5.79 price target, but the stock faces headwinds from weak consumer demand and negative cash flow trends.
The outlook is cautious; while cost discipline supports margins, persistent revenue weakness and negative profitability pose significant risks. The stock's low P/S ratio of 0.42 may attract value investors, but sustained operational improvements are needed for a durable recovery amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
